FDA Accepts Supplement Application for Danziten (Nilotinib Tartrate)
The FDA has accepted a supplemental application for Danziten, which contains nilotinib tartrate.
Asset / Drug
Drug and asset intelligence for AZURITY with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Tyrosine Kinase Inhibitor
No catalysts indexed for this entity yet.
Monitor the timeline for FDA review outcomes and any subsequent market entry strategies from AZURITY.
July 3, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.